<DOC>
	<DOCNO>NCT00128713</DOCNO>
	<brief_summary>The primary objective study compare three study arm low , medium , high dose platelet therapy respect percentage patient experience least one episode Grade 2 high bleeding determine Platelet Dose Trial Bleeding Scale ( Grade 2 bleed corresponds bleed moderate , severe enough warrant red blood cell transfusion ) . There number secondary endpoint related platelet transfusion , hemostasis , concern . The four important secondary endpoint compare three study arm respect follow outcome : 1 ) platelet utilization rate ( total number platelet transfuse x 10 ^11 ) ; 2 ) number platelet transfusion event ( frequency transfusion ) ; transfusion event would define separate platelet transfusion issue study site 's transfusion service ; 3 ) high category bleeding time study ( Platelet Dose Trial Bleeding Scale Grades le equal 1 , 2 , 3 , 4 arm ) ; 4 ) bleed severity base number day bleed ( total day bleed bleeding/thrombocytopenic day ) , intensity bleeding , number site bleed ( severity score validate publish time study complete ) .</brief_summary>
	<brief_title>Optimal Platelet Dose Strategy Management Thrombocytopenia</brief_title>
	<detailed_description>BACKGROUND : It important identify safe cost effective strategy provide platelet support achieve effective disease management without deplete platelet supply . Informative clinical data provide concern platelet transfusion trigger . In contrast , optimal quantity platelet use per transfusion remain highly controversial subject . No prospective platelet transfusion study perform patient randomize assigned platelet dose throughout period thrombocytopenia . DESIGN NARRATIVE : After obtain consent verify eligibility requirement , patient randomize one three dos prophylactic platelet transfusion ( low , medium , high dose ) . The dosage base patient 's body surface area ( BSA ) . The dose target follow : 1 ) low dose 1.1 x 10^11/m² ; 2 ) medium dose 2.2 x 10^11/m² ; 3 ) high dose 4.4 x 10^11/m² . A dose within 25 % value either direction consider target range . For many adult patient , typical dose one unit apheresis platelet would fall target range medium dose . All prophylactic transfusion provide patient study give accord randomize target dose range . Only blood bank staff , clinical staff , access target dose range patient . The patient 's morning platelet count take every day . If value le equal 10,000 , prophylactic platelet transfusion give . Otherwise , prophylactic platelet transfusion give day . Platelet transfusion may give time , dose , treat active bleed association invasive procedure . A hemostatic assessment carry every day identify bleed patient may experience . This assessment involve patient interview , physical assessment , chart review . Data transfusion ( e.g. , platelet red blood cell ) , transfusion-related event , serious adverse event , protocol deviation also record . Patients participate study either 30 day initial platelet transfusion , receive platelet transfusion 10 day recent platelet transfusion , hospital discharge ( whichever come first ) . Each three pairwise dose comparison interest . Therefore , primary secondary endpoint analyze use three separate pairwise comparison , 0.017 significance level adjust multiple comparison . This study approve National Heart , Lung , Blood Institute ( NHLBI ) -appointed protocol review committee data safety monitor board ( DSMB ) , participate institution 's institutional review board . An interim monitoring plan develop protocol team DSMB , describe protocol . The study monitor accordance plan .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Has , expect , hypoproliferative thrombocytopenia , expect platelet count 10,000 ul least 5 day hospital least 5 day Weight 10 135 kilogram PT/INR , PTT , fibrinogen assay measure within 72 hour study entry follow : 1 . PT le equal 1.3 time upper limit normal laboratory 2 . PTT le equal 1.3 time upper limit normal laboratory 3 . Fibrinogen great equal 100 mg/dl Undergoing , complete , hematopoietic stem cell transplantation , diagnosis ; OR diagnosis acute chronic leukemia , nonHodgkins Hodgkins lymphoma , myeloma , myelodysplasia , nonhematologic malignancy undergoing , complete , chemotherapy During hospitalization , patient yet receive platelet transfusion relate current planned course therapy ( individual platelet transfusion give prior study unrelated thrombocytopenia exclude patient ) Evidence great equal Grade 2 bleeding ( determined Platelet Dose Trial Bleeding Scale ) Receiving antithrombotic drug Will receive bedside leukoreduced platelet transfusion Present , history , platelet transfusion refractoriness within 30 day prior study entry Preenrollment lymphocytotoxic antibody screen ( PRA ) know great equal 20 % base prior data Present , history , acute promyelocytic leukemia ( APML ) , immune thrombocytopenic purpura ( ITP ) , thrombotic thrombocytopenic purpura ( TTP ) , hemolyticuremic syndrome ( HUS ) Will transfuse platelet trigger great 10,000 platelets/ul Recent history major surgery ( within 2 week study entry ) Currently take , participate study involve , platelet substitute , platelet growth factor , pharmacologic agent intend enhance decrease platelet hemostatic function Pregnant Previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Blood Transfusion</keyword>
	<keyword>Blood Platelets</keyword>
</DOC>